153 related articles for article (PubMed ID: 32604058)
1. Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
Kallen ME; Koka R; Singh Z; Sanchez-Petitto G; Zaman QU; Yared JA; Duong VH
Leuk Res; 2020 Sep; 96():106406. PubMed ID: 32604058
[No Abstract] [Full Text] [Related]
2. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
DiNardo C
Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
[No Abstract] [Full Text] [Related]
3. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
5. Positive First Trial of Enasidenib for AML.
Cancer Discov; 2017 Aug; 7(8):OF1. PubMed ID: 28659444
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.
Stein EM
Future Oncol; 2018 Jan; 14(1):23-40. PubMed ID: 29243965
[TBL] [Abstract][Full Text] [Related]
7. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
Roboz GJ
Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
[No Abstract] [Full Text] [Related]
8. Molecular remission and response patterns in patients with mutant-
Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
[TBL] [Abstract][Full Text] [Related]
9. Enasidenib for the treatment of acute myeloid leukemia.
Dugan J; Pollyea D
Expert Rev Clin Pharmacol; 2018 Aug; 11(8):755-760. PubMed ID: 29770715
[TBL] [Abstract][Full Text] [Related]
10. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
11. Enasidenib: First Global Approval.
Kim ES
Drugs; 2017 Oct; 77(15):1705-1711. PubMed ID: 28879540
[TBL] [Abstract][Full Text] [Related]
12. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
13. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
14. Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
Khan M; Roddy JT; Hernandez JR; Bursch K; Bal N; Carlson KS; Bergl PA
Br J Haematol; 2021 Sep; 194(6):1083-1085. PubMed ID: 34101165
[No Abstract] [Full Text] [Related]
15. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
[TBL] [Abstract][Full Text] [Related]
16. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
17. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations.
Galeotti J; Coombs CC
Br J Haematol; 2019 Feb; 184(4):496. PubMed ID: 30334576
[No Abstract] [Full Text] [Related]
18. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of enasidenib for the treatment of acute myeloid leukemia.
Del Principe MI; Paterno G; Palmieri R; Maurillo L; Buccisano F; Venditti A
Expert Opin Pharmacother; 2019 Nov; 20(16):1935-1942. PubMed ID: 31454277
[No Abstract] [Full Text] [Related]
20.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
